

**REMARKS**

Upon entry of the amendment, claims 1, 8-10, 14-20, 25, 29, 31, 34, 41-43, 47-53, and 58 will be pending. The specification has been amended to insert a priority statement, make reference to the sequence listing that was filed with the parent application, correct obvious typographical errors, and to update references to filed patent applications that are now published.

The Applicants submit that these amendments do not constitute new matter.

**FEES**


It is believed that no fee is due with this amendment. However, if a fee is due, the Commissioner is hereby authorized to charge the Deposit Account 50-0252 referencing case number ISIS-0543US.

**CONCLUSIONS**

In view of these amendments and remarks, the Applicants believe that the case is now in proper form for examination. A prompt office action on the merits of the case is requested.

Respectfully submitted,

Date: Feb 14, 2006

  
Colleen J. McKiernan, Ph.D.  
Agent for Applicant  
Reg. No. 48,570

IISIS PHARMACEUTICALS, INC.  
1896 Rutherford Road  
Carlsbad, CA 92003

Phone: 760-603-2722  
Fax: 760-603-3820